Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Gains from Sales and Divestitures (2017 - 2025)

Coherus Oncology (CHRS) has disclosed Gains from Sales and Divestitures for 12 consecutive years, with $528673.0 as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures fell 81.08% to $528673.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $528673.0 through Dec 2025, down 81.08% year-over-year, with the annual reading at $528673.0 for FY2025, 81.08% down from the prior year.
  • Gains from Sales and Divestitures hit $528673.0 in Q4 2025 for Coherus Oncology, down from $2.8 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $2.8 million in Q4 2024 to a low of $465930.0 in Q4 2021.
  • Historically, Gains from Sales and Divestitures has averaged $1.2 million across 5 years, with a median of $806854.0 in 2022.
  • Biggest five-year swings in Gains from Sales and Divestitures: surged 118.1% in 2024 and later tumbled 81.08% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $465930.0 in 2021, then soared by 73.17% to $806854.0 in 2022, then skyrocketed by 58.75% to $1.3 million in 2023, then soared by 118.1% to $2.8 million in 2024, then tumbled by 81.08% to $528673.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for CHRS at $528673.0 in Q4 2025, $2.8 million in Q4 2024, and $1.3 million in Q4 2023.